Boston Therapeutics (BTHE) 0.5388 $BTHE
Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist
Marketwire - Wed Jul 09, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology. He will serve as the primary liaison to the Company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the Board of Directors' Scientific Advisory Committee.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jun 19, 10:53AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature three emerging growth companies on Fox Business nationwide on Thursday, June 19, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, June 21, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, June 22, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday June 22, 2014 at 3:30 p.m. HKT.
Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes
Marketwire - Thu May 29, 6:02AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, has initiated a Phase IIb clinical study to assess the efficacy and safety of SUGARDOWN(R) in 24 patients with Type 2 diabetes taking metformin. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY under the direction of Principal Investigator Mitchell D. Efros, MD, FACS.
Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29
Marketwire - Tue May 27, 7:05AM CDT
Boston Therapeutics, Inc. (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today announced that President Kenneth A. Tassey, Jr. will present at two upcoming conferences. Mr. Tassey will provide an overview of the Company, recent business developments and growth strategy.
SeeThruEquity 3rd Annual Microcap Investor Conference To Be Held May 28, 2014
ACCESSWIRE - Thu May 22, 8:11AM CDT
Conference Being Held at Convene Grand Central in Midtown
SeeThruEquity Issues Quarterly Update on Boston Therapeutics and Raises Price Target to $1.12
ACCESSWIRE - Wed May 21, 9:38AM CDT
New York, NY / ACCESSWIRE / May 21, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Boston Therapeutics (OTCQB: BTHE) for Q1 2014.
Boston Therapeutics Announces Strategic Marketing Agreement With Benchworks SD Aimed at Growing Sales of SUGARDOWN(R)
Marketwire - Tue May 20, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) a leading developer of compounds that address blood sugar management and inflammatory disease using complex carbohydrate chemistry, today announced the signing of a strategic marketing agreement with Benchworks SD, LLC, a leading branding and marketing agency, with the goals of driving brand awareness and growing sales of SUGARDOWN(R) (http://www.sugardown.com).
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013.
Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France.
Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately.
Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes.
Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Appoints Three to Management Positions
Marketwire - Tue Dec 10, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company" , an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.
Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist
Marketwire - Wed Jul 09, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology. He will serve as the primary liaison to the Company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the Board of Directors' Scientific Advisory Committee.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jun 19, 10:53AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature three emerging growth companies on Fox Business nationwide on Thursday, June 19, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, June 21, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, June 22, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday June 22, 2014 at 3:30 p.m. HKT. Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes
Marketwire - Thu May 29, 6:02AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, has initiated a Phase IIb clinical study to assess the efficacy and safety of SUGARDOWN(R) in 24 patients with Type 2 diabetes taking metformin. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY under the direction of Principal Investigator Mitchell D. Efros, MD, FACS.
Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29
Marketwire - Tue May 27, 7:05AM CDT
Boston Therapeutics, Inc. (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today announced that President Kenneth A. Tassey, Jr. will present at two upcoming conferences. Mr. Tassey will provide an overview of the Company, recent business developments and growth strategy.
SeeThruEquity 3rd Annual Microcap Investor Conference To Be Held May 28, 2014
ACCESSWIRE - Thu May 22, 8:11AM CDT
Conference Being Held at Convene Grand Central in Midtown
SeeThruEquity Issues Quarterly Update on Boston Therapeutics and Raises Price Target to $1.12
ACCESSWIRE - Wed May 21, 9:38AM CDT
New York, NY / ACCESSWIRE / May 21, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Boston Therapeutics (OTCQB: BTHE) for Q1 2014.
Boston Therapeutics Announces Strategic Marketing Agreement With Benchworks SD Aimed at Growing Sales of SUGARDOWN(R)
Marketwire - Tue May 20, 6:01AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) a leading developer of compounds that address blood sugar management and inflammatory disease using complex carbohydrate chemistry, today announced the signing of a strategic marketing agreement with Benchworks SD, LLC, a leading branding and marketing agency, with the goals of driving brand awareness and growing sales of SUGARDOWN(R) (http://www.sugardown.com).
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013. Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France. Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately. Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes. Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Appoints Three to Management Positions
Marketwire - Tue Dec 10, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately. 
